Start-Up Quarterly Statistics, Q2 2013
This article was originally published in Start Up
Executive Summary
The year might have started off slow for start-up fundraising ($398.7 million in Q1), but during the second quarter of 2013 life science companies rallied and earned a whopping $907.2 million. There were several reverse licensing arrangements as well as alliances involving large molecule-focused start-ups.
You may also be interested in...
J&J’s Boston “Deal-Making Machine” Backs Two Start-Ups
The third of Johnson & Johnson’s four Innovation Centers, designed to give the behemoth company access and proximity to early-stage scientific innovation, opened June 27 in Boston. Concurrently, the company backed two VC-funded young start-ups , as well as a hospital alliance and a laboratory initiative.
J&J Buys Aragon, Boosting Prostate Cancer Franchise Beyond Zytiga
The buyout gives J&J Aragon’s androgen receptor inhibitor similar to Medivation’s Xtandi, a potential blockbuster and competitor. In the process, Aragon’s investors will back new spinout Seragon, created to house an estrogen receptor blocker.
Second Genome Scores A Deal With Janssen, A First In The Field Of Microbiome Therapeutics
Second Genome’s ulcerative colitis research alliance with Janssen Biotech is a first in the burgeoning microbiome therapeutics space, which may be transitioning from venture investment to commercial partnering. But is the deal an inflection point or a fluke?